Hexavalent Vaccine Could Significantly Improve India's Immunisation Programme

A comprehensive study by the Union Health Ministry and partner organizations released in August 2026 demonstrates that introducing a hexavalent vaccine (combining six vaccinations in one shot) into India's Universal Immunisation Programme (UIP) could substantially reduce the number of injections children receive while improving vaccination coverage rates and healthcare delivery efficiency.

Context: India's UIP is among the world's largest immunization programs, reaching 26+ crore children annually across all districts. Currently, the program requires multiple separate injections for diphtheria, tetanus, pertussis, polio, hepatitis-B, and Haemophilus influenzae type-b (Hib) protection, administered in different visits. The multiple-injection approach creates several challenges: (1) vaccine hesitancy due to injection burden, particularly in rural areas; (2) incomplete immunization schedules due to missed follow-up visits; (3) increased healthcare worker time and cold-chain burden; (4) higher dropout rates between vaccination rounds. The hexavalent vaccine combines these six diseases into a single injection, addressing multiple bottlenecks simultaneously.

The study found that hexavalent introduction would reduce total injections per child by approximately 50% during the primary immunization schedule (0-12 months), improve on-time vaccination completion rates, decrease healthcare system workload, and reduce wastage. Global evidence (from developed nations and middle-income countries) shows hexavalent reduces dropout rates significantly. Cost-benefit analysis in the study indicated that while the hexavalent vaccine has higher per-unit cost than monovalent vaccines, the overall program cost decreases when accounting for reduced healthcare delivery expenses, improved coverage, and disease prevention benefits. India currently uses pentavalent (5 diseases) in its schedule; hexavalent would be the next-generation advancement.

For exam purposes: This involves public health policy, vaccine development, and UIP implementation—UPSC's persistent focus areas. Likely questions: "Evaluate the potential impact of hexavalent vaccines on India's immunization program. What are barriers to introducing new vaccines in India?" Relevant for understanding India's health infrastructure, immunization policy evolution, and public health innovation. The decision involves cost-effectiveness analysis, healthcare equity, and child health outcomes—all UPSC staples.